Congrats the the GI Windows Surgical team on raising $37M in its Series B round! The funding will support continued progress in clinical development and commercialization of its Self-Forming Magnet, FlexagonTM and delivery systems. GI Window's technology employs magnetic anastomosis to enable less invasive surgery - a significant and very exciting breakthrough in the field! Read more about it here: https://lnkd.in/gTCfxzVD
Sonder Capital
Venture Capital and Private Equity Principals
San Carlos, CA 1,232 followers
Committed to creating a new standard of care.
About us
Investing in life-changing healthcare technologies.
- Website
-
http://www.sondercapital.com
External link for Sonder Capital
- Industry
- Venture Capital and Private Equity Principals
- Company size
- 2-10 employees
- Headquarters
- San Carlos, CA
- Type
- Partnership
- Founded
- 2019
Locations
-
Primary
Get directions
San Carlos, CA, US
Employees at Sonder Capital
Updates
-
Congrats to the Jupiter Endovascular team for treating their first patient in the US! This milestone was achieved soon after the company's first two patients were treated in Poland in September. Way to go!
First in the USA! This week, Mitchell Weinberg and Vincent Gallo performed the first #Endoportal Control procedure in the US at Northwell Health Staten Island University Hospital, where they successfully treated the first pulmonary embolism patient in the SPIRARE II pivotal trial using the Vertex Pulmonary Embolectomy System. This significant milestone in our quest to revolutionize endovascular medicine builds upon the momentum from our recent FDA IDE approval and our first cases in the currently-enrolling SPIRARE I European study. We would like to extend a big thank-you to our SPIRARE investigational team for their support and dedication, and to Brandon Dilluvio, CCRC in particular for his support in facilitating this first US procedure. Read more: https://lnkd.in/gv4frN7b *The Vertex Pulmonary Embolectomy System is for investigational use only.
-
-
A huge welcome to Deborah K., Sonder Capital's newest Venture Partner! Deb is the former CEO of Evidation Health and co-founder of MedtechWOMEN. Her background in medical devices coupled with her expertise in digital health technology will strengthen Sonder's ability to navigate and identify future investments in the medtech sector as it rapidly evolves to integrate multi-modal health data and AI. We couldn't be more thrilled to add such a rockstar to our team! Read the full release here: http://bit.ly/48oOcPz
-
-
Welcome to the Vitestro board Dave Hickey! We are excited to work alongside you to make Vitestro a big success. Your knowledge and experience in the industry will be a very valuable addition.
We are excited to welcome Dave Hickey, former Executive Vice President and President of BD’s Life Sciences Segment, to Vitestro’s Board of Directors as an independent board member! Dave brings a wealth of experience from his impressive career in healthcare, most recently serving at BD, where he successfully scaled global operations. Notably, he led BD’s response during the COVID-19 pandemic, developing numerous rapid and molecular diagnostic tests in record time to support healthcare providers and patients worldwide. As Vitestro expands into the US market, Dave’s extensive knowledge in the specimen collection field and his leadership in launching innovative diagnostic solutions will be instrumental in shaping our next steps. His fresh perspective and deep industry expertise will be invaluable as we continue our mission to revolutionize phlebotomy with autonomous technology. Dave Hickey joined Vitestro’s board alongside other industry leaders including Dr. Fred Moll, co-founder of Intuitive Surgical and Auris Health. Please join us in welcoming Dave to the team! #Vitestro #BoardUpdate #MedTech #Phlebotomy
-
-
Congrats to Sonder Capital portfolio company, Jupiter Endovascular, for treating its first two patients in its first in-human clinical trial! What an amazing achievement! Well-done and congrats to the team! Read the full press release here: https://bit.ly/3XzlWoF
The world's first-ever interventional procedure using #Endoportal Control was performed last week on September 10, 2024 by Krzysztof Bartus MD PhD, Grzegorz Kopec, and Jakub Stepniewski at the St. John Paul II Hospital in Krakow, Poland, where they used the Vertex Pulmonary Embolectomy System for the first time to successfully treat a patient with acute pulmonary embolism as part of the SPIRARE I clinical study. This marks a momentous milestone in our quest to revolutionize endovascular medicine. A big congratulations and thank-you to the SPIRARE I investigators for this monumental achievement! Read more: https://bit.ly/3XzlWoF *The Vertex Pulmonary Embolectomy System is for investigational use only.
-
-
We are excited to announce that Andy McGibbon, one of our founding partners, is transitioning to an operational role as the Head of Strategy for the US at Vitestro – a Sonder portfolio company we’ve been proud to support. Andy has been a key member of the Sonder team since inception, from raising our first fund in a room with barely enough space on the table for 3 laptops, through the pandemic roller coaster, and beyond. His contributions have been instrumental in guiding our investment strategy, supporting our portfolio companies as a board member, and building strong relationships with those throughout the early stage medtech ecosystem. While we will miss his daily presence, we are thrilled about this opportunity for Andy and Vitestro. We’re also pleased to announce that Andy will continue as an Operating Partner at Sonder, lending his expertise and network to identify promising medtech opportunities and support our mission of building the early stage medtech ecosystem. On behalf of the entire Sonder team, we extend our heartfelt gratitude to Andy for his contributions, and we look forward to seeing the successes at Vitestro!
-
A huge congratulations to our portfolio company, Vitestro, for becoming the first company to achieve CE marking for an autonomous blood drawing device! Read the full press release here: https://hubs.la/Q02MRgWf0
🎉Exciting news: 𝗼𝘂𝗿 𝗮𝘂𝘁𝗼𝗻𝗼𝗺𝗼𝘂𝘀 𝗯𝗹𝗼𝗼𝗱 𝗱𝗿𝗮𝘄𝗶𝗻𝗴 𝗱𝗲𝘃𝗶𝗰𝗲 𝗵𝗮𝘀 𝗿𝗲𝗰𝗲𝗶𝘃𝗲𝗱 𝗖𝗘 𝗺𝗮𝗿𝗸𝗶𝗻𝗴! This significant milestone confirms that our device meets the requirements of the European Medical Device Regulation and is now approved for commercial use across the European Union. Notably, we are the first company ever to achieve CE marking for an autonomous blood drawing device. With the CE marking secured, we look forward to the implementation at European hospitals who have ordered our device: OLVG Lab BV | St. Antonius Ziekenhuis | Result Laboratorium | Odense University Hospital Read the full press release here: https://hubs.la/Q02MRgWf0 #MedTech #BloodDraw #Phlebotomy #CEmarking
-
-
Another win for Sonder Capital portfolio company, Neptune Medical, who recently raised $97M in their Series D financing! In addition to the company's highly successful and oversubscribed fundraising round, Neptune also spun out Jupiter Endovascular, a company focused on treating pulmonary embolisms. Congratulations to the whole team! Read more about it here: https://lnkd.in/gzpqJW4D
-
Great insights in the mid-year 2024 HSBC Healthcare Venture report! Check out the report here: https://grp.hsbc/6046ibOAs
We’re excited to announce the release of our mid-year Venture Healthcare Report for 2024, covering deep sector-specific observations and predictions across biopharma, med devices, healthtech, and Dx/tools. Click here to check out the full report: https://grp.hsbc/6046ibOAs #HSBCInnovationBanking
-
-
Another big win for Sonder Capital portfolio company, Spirair, who announced that it has received 510(k) clearance from the FDA for its SeptAlign™ System, following FDA clearance of the SeptAlign bioabsorbable implant in August 2023. This represents Spirair’s final step in completing the FDA clearance process for the SeptAlign System. SeptAlign is a minimally invasive treatment for nasal septal deviation, one of the most common causes of nasal airway obstruction. Treatment can be performed at any service site and under local anesthesia, and has been clinically demonstrated to straighten minor cartilaginous septal deviation. Congrats to the Spirair team! Well done! Read the full press release here: https://bit.ly/3wh4tYp
Spirair Receives FDA Clearance for SeptAlign
https://spirair.com